Takeda Pharmaceutical Profit Margin

The latest profit margin for TAK is 3.91% as of June 2026. That compares with 3.06% in the prior-year period — up 27.9% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Takeda Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, TAK's profit margin moved from 3.06% to 3.91% — a 27.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Takeda Pharmaceutical's valuation or profitability profile.

Against Healthcare companies, TAK currently prints 3.91% for profit margin, while the sector average sits near 15.29%. That is roughly 74.4% below the sector mean. Large gaps often invite a closer look at Takeda Pharmaceutical's growth, margins, and balance sheet.

Profit Margin shows how effectively Takeda Pharmaceutical converts resources into returns. At 3.91%, TAK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 3.06% in the prior-year period — up 27.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TAK's profit margin (3.91%), review year-over-year change from 3.06%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.